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New directions included:
• Radiation effects on the cell, tumor, and normal tissue
can be exploited so that schedules beyond the conven-
tional and still useful 2 Gy fraction can be utilized.
Different radiation dose, type, and schedule (multifrac-
tion) can potentially act “as a drug,” with unique and
exploitable mechanism of action. This concept pertains
to radiation alone and with molecular-targeted therapy
and immunotherapy.
• Utilizing biomarkers of radiotherapy in precision medi-
cine to assess both treatment efficacy and normal tissue
damage, potentially including organ-specific biomarkers
of tissue damage.
Controversies to:
• Defining the most resistant subpopulation within a
tumor, particularly at higher fractional doses.
Ameliorating resistance could include targeting tumor
cells and/or the vasculature.
• Rethinking the target and extent of tumor volume irra-
diated as potential new strategies for enhancing cura-
tive benefit and avoiding normal tissue toxicity with
preservation of organ function.
Current challenges in:
• Defining radiation parameters for selected target
induction, such as a survival pathway, tumor antigen,
enhanced immune response, or change in vasculature.
• Determining the duration in the change of radiation- 
inducible phenotype to be exploited.
• Eventually modifying the treatment from the “time-honored” 
approaches.
Altogether, these approaches can facilitate the incorpora-
tion of radiation technology and biology into treatment 
strategies for personalized medicine, including molecular 
and immune-targeted therapies.
RepoRt
The National Cancer Institute’s Radiation Research Pro-
gram hosted the workshop “Shades of Gy (gray): Bio-
logical Consequences of Radiation Therapy” on September 
11–12, 2017 (agenda; https://dctd.cancer.gov/NewsEvents/
IntRoduCtIon
The ability to physically target radiotherapy using image-
guidance is continually improving with photons and par-
ticle therapy that include protons and heavier ions such 
as carbon. The unit of dose deposited is the gray (Gy); 
however, particle therapies produce different patterns 
of ionizations, and there is evidence that the biological 
effects of radiation depend on dose size, schedule, and 
type of radiation. This National Cancer Institute (NCI)– 
sponsored workshop addressed the potential of using 
radiation-induced biological perturbations in addition to 
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biological_consequences_of_radiation_therapy_workshop_
agenda.pdf). The focus is a novel concept of defining radia-
tion dose both in energy deposition (Gy) and biologically 
meaningful perturbations in the tumor and normal tissue. 
This is intended to broaden the application of radiotherapy 
in precision medicine. The workshop’s long-term goal is to 
build from a combination of well-known reliable models, 
new cancer biology, and clinical experience to develop new 
paradigms for clinical cancer care.
Norman Coleman (NCI) opened the workshop stress-
ing the potential use of radiation as a drug with radiation 
dose described in appropriate units similar to drug therapy 
such as pharmacokinetics and pharmacodynamics. This 
requires returning to fundamental processes including 
the mechanism(s) of radiation damage, biophysics, stress 
and adaptive responses, and tumor microenvironment 
effects under the umbrella of “Accurate, Precision Radia-
tion Medicine.” The importance of physical dose remains 
paramount. Emphasizing ambiguous terminology in use 
is that the unit “gray” used in biodosimetry is actually 
a biological change (a “biodose”) and not the physical 
dose. The new paradigm for biological dose in addition to 
physical dose uses modern molecular endpoints that can 
improve cancer care.
Several challenging issues on current radiation “Dose-
Effect Models” were discussed in Session I. Soren Bentzen 
(University of Maryland, Baltimore, MD) stressed the impor-
tance of a normalized dose-response gradient that would 
allow the tumor control probability/normal tissue compli-
cation probability percentage versus total radiation dose 
when given as 1.8 Gy per fraction to be predicted for radia-
tion plus chemotherapy or immunotherapy and all three 
treatments combined. He suggested the use of the linear 
quadratic (LQ) EQD2α/β to predict actual clinical outcome 
in patients with head and neck squamous cell cancer and to 
compare the LQ model with treatment biomarkers ranging 
from biological to imaging markers that can provide integral 
effects of dose and time for tumor and normal tissue. This 
approach could provide lead time for changes in treatment, 
thereby improving both cancer treatment outcomes and 
quality of life. Dr. Martin Brown (Stanford University, Stan-
ford, CA) supported the use of the LQ model and pointed 
out key exceptions to their use, such as the role of the 
tumor stroma and tumor vasculature in determining tumor 
radiation sensitivity, for which the endpoint TCD50 (dose 
to control 50% of the murine tumors irradiated) should 
be adopted. He asserted that radiosensitivity of tumors is 
only relevant to tumor control if the radiation-damaged 
vasculature is restored by bone marrow–derived cells (1). 
Blocking the SDF-1/CXCR4 pathway would block the bone 
marrow–derived cell’s recruitment and increase tumor con-
trol, with the added benefit of protecting normal tissues. 
Philip Lambin (Maastricht University, Maastricht, the Neth-
erlands) discussed that the LQ models should be revisited 
to understand whether low or high α/β-ratio tumors can 
be explained with modern molecular biological endpoints, 
and he also suggested to study whether a tumor is slowly 
or rapidly proliferating. He proposed that to help predict 
treatment response and overall survival, quantitative imag-
ing radiomics (with three-dimensional dose delivery and 
four-dimensional radiomics) would enable the measure of 
proliferation signatures and other tumor parameters that 
would help link classical α/β concepts with relevant biology 
such as DNA repair, proliferation, and reoxygenation.
That basic biophysics provides a great deal of infor-
mation on radiation effects and also supports the need 
for biological assessment to enhance physical dose was 
discussed in Session II. The track structure patterns of 
ionization and excitation from various radiation particle 
types and their secondary charged particles in complex 
biological media (cells in suspension or in tissue and spe-
cific subcellular targets) are not clear, particularly at low 
incident energies, where the energy transfer is most pro-
nounced. Dudley Goodhead (Medical Research Council, 
London, United Kingdom) and Jan Schuemann (Massa-
chusetts General Hospital, Boston, MA) discussed the latest 
progress in Monte Carlo simulations of track–structure 
interactions with biological structures and concluded that 
at the nanometer level of cellular targets, radiation dose, 
dose rates, and fractions in radiotherapy would have to be 
so much higher than those used clinically to have overlaps 
of multiple primary tracks in the target volumes involved 
in the initial physical damage. Overall, track structure 
provides physical data that indeed inform microdosimetry, 
but cellular response requires much more knowledge of 
biological response functions, such as relative biological 
effectiveness, RBE (the RBE is defined as the ratio of the 
doses required by two types of radiation to cause the same 
level of effect). Thus, the RBE depends on the dose and 
the biological endpoint. Lisa Cornell (NASA, Norfolk, VA) 
and Francis Cuccinota (University of Nevada, Las Vegas, 
Las Vegas, NV) reviewed the importance of track structure 
coupled with biophysical models in space radiation pro-
tection in which heavy ions present the major biological 
threats to astronauts. In summary, track structure provides 
the qualitative understanding of the different RBEs from 
the variety of radiation modalities used in therapy, and 
with the addition of biological-response models, track-
structure results can be more realistically extrapolated to 
estimate the biological effects of any incident radiation.
Session III transitioned from physical dose to biological 
effects, focusing on the RBE of particles compared with 
photons. The rationale for defining RBE in this manner as 
a ratio is to allow extrapolation of the vast clinical experi-
ence with photon therapy to particle treatment. It is argued 
that the very concept of RBE is questionable because, bio-
logically, protons and heavier ions are very different from 
photons. Kevin Prise (Queen’s University Belfast, Belfast, 
Northern Ireland, United Kingdom) stressed the fact that 
one of the sources of uncertainty of RBE is the biological 
effects of the reference photon. For protons, the clinically 
used RBE is assumed to have a fixed value of 1.1, mostly 
obtained from in vitro and in vivo measurements carried out 
under inconsistent and inadequately defined conditions. 
The use of a simple ratio is challenged. Cläre von Neubeck 
(German Cancer Consortium Partner Site Dresden and 
German Cancer Research Center, Heidelberg, Germany) 
pointed out that analyses of clinical response to assess 
RBE should take into account interpatient heterogeneity 
associated with the tumor (size, grade, location, infectious 
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status, and mutations) and also preexisting medical condi-
tions, life style habits, and other factors. Jeffrey Buchsbaum 
(NCI) pointed out that a major concern in proton therapy 
is the unanticipated severe toxicities that may be attribut-
able to higher RBE at the distal and lateral beam edges. The 
suggested approach is a “continual reassessment model” 
to improve the understanding of the RBE variability based 
on data for populations of patients and with the help of 
artificial intelligence approaches to translate the knowl-
edge continually into clinical applications. Roger Howell 
(Rutgers University, Newark, NJ) discussed that the RBE 
of targeted radionuclides that are widely used as standard 
of care to sterilize metastatic disease needs reevaluation. 
An interesting proposal is to formulate RBE in terms of 2 
Gy equivalent fraction (EQD2) to relate it to conventional 
radiotherapy, but the type of radionuclide has great impact, 
for example, auger electron emitters can be more radiotoxic 
than alpha emitters (RBE as high as 8). Manjit Dosanjh 
(CERN, Geneva, Switzerland) emphasized the difference in 
protons and heavier ions with unique molecular and cellu-
lar responses compared with photons due to the complex-
ity of DNA damage, differential gene expression, epigenetic 
modulation, and effect on cell cycle. Such differences will 
have profound clinical consequences.
Clearly, biomarkers and response predictors are needed 
to measure “radiation effects.” The discussion in Session IV 
reviewed key issues including: optimal timing and source 
of the marker (tumor, biofluid, and imaging) and the 
need for reproducibility, standardization, and validation 
techniques including FDA approval. Biomarkers for organ 
injury may benefit from biodosimetry studies done for 
radiation incidents, although there are obvious differences 
in exposure. In both settings, predictive assays that accu-
rately estimate the risk of injury to specific organ systems 
are of particular importance. Cytogenetic assays, including 
assessment of micronuclei and dicentric chromosomes, 
and γH2AX expression in lymphocytes are used. Newer bio-
dosimetry approaches including metabolomics and quanti-
fying circulating markers such as long noncoding RNA and 
miRNA may provide tumor response and organ-specific 
injury prediction (2–5). For therapeutic interventions, the 
goal is the integration of biomarkers of tumor and normal 
tissue response into a predicted biological outcome that 
allows personalization of the radiation treatment plan and 
dose appropriate for each patient based on the probability 
of individual organ toxicity and tumor control. Careful 
consideration should be given to circulating tumor cells 
(CTC) as a biomarker of tumor response, particularly in ref-
erence to local versus systemic recurrence, but also the use 
of other markers within the field of “liquid biopsy” such as 
ctDNA or exosomes.
Session V discussed the clinician’s perspective on “dose” 
with outcomes and next generation of standard of care. 
Four speakers described topics of stereotactic body radio-
therapy (SBRT)/hypofractionation (Bob Timmerman, Uni-
versity of Texas Southwestern Medical Center, Dallas, TX), 
RBE of proton therapy (Harald Paganetti, Massachusetts 
General Hospital), novel role of radiation for chemopoten-
tiations (Iris Eke, NCI), and next generation of personal-
ized radiation medicine (Quynh Le, Stanford University). 
Maximizing the therapeutic index was a key focus of these 
innovative strategies. With the delivery of high dose radia-
tion in a hypofractionated manner for photons and particle 
therapy, the quality assurance of physical dose delivery 
precision in imaging, motion control, and dose modula-
tion is of paramount importance because such high doses 
delivered in just a few fractions cannot depend on repair 
of normal tissues to maximize the therapeutic index. The 
potential role of SBRT in managing oligometastasis or oli-
goprogression exists but must be evaluated in randomized 
trials in order to understand its indications, limitations, 
and biological effects (6). New preclinical data were pre-
sented demonstrating that multifractionated radiotherapy 
was effective in upregulating integrin and mTOR/AKT sign-
aling, leading to enhanced sensitivity to drugs induced by 
radiation, a proof of concept for the use of understanding 
the biological impact of radiation beyond dose (7). The use 
of patient-derived xenograft models to predict sensitivity to 
molecular-targeted therapies in combination with radio-
therapy should be interrogated in a systematic manner 
in order to better understand their roles and limitations. 
Finally, there are trials evaluating personalized radiation 
using imaging, biology, circulating biomarkers such as 
ctDNA, and radiogenomics to maximize tumor control 
and/or to identify patients at risk for normal tissue toxic-
ity (8, 9). To date, none can be applied in routine clinical 
practice.
With the general agreement that the biological descrip-
tion is critical in addition to physical dose, biological con-
sequences of clinical relevance were discussed in Session 
VI. David Kirsch (Duke University, Durham, NC) summa-
rized several technologies for the application of genetically
engineered mouse models and described the importance
of fully immune-competent models to the understanding
of radiotherapy, immunotherapy, radiation-induced car-
cinogenesis, normal tissue injury, and the cell-autonomous
and non–cell-autonomous mechanisms that contribute to
normal and tumor tissue response to radiation. Phuoc
Tran (Johns Hopkins University, Baltimore, MD) high-
lighted mechanisms by which radiation can enhance anti-
tumor immune response, including increased expression of
immune mediators and the development of micronuclei.
Centrosome clustering can result in the selective killing of
cancer cells with supernumerary centrosomes and increase
in micronuclei by forcing cells into multipolar divisions.
Drugs may enhance the cytotoxic effects of radiation while
concurrently potentiating radiation-induced antitumor
immunity through generation of micronuclei. Amit Maity
(University of Pennsylvania, Philadelphia, PA) focused
on combinations of molecular targeted agents with radio-
therapy. Agents targeting the PI3K/Akt pathway affected
EGFR and VEGF function to restore radiation sensitivity.
Radiation combination clinical trials involving agents in
DNA damage repair pathway inhibitors were noted, includ-
ing inhibitors of ATM, ATR, DNA-PK, RAD51, WEE1, and
PARP. Joanne Weidhaas (UCLA, Los Angeles, CA) discussed
the genetics and biological consequences of miRNA germ-
line mutations in radiation response. Genetic mutations in
miRNA can alter radiation response. MiRNAs can inhibit
oncogene signaling or enhance tumor suppressor targeting.
Published OnlineFirst April 23, 2018; DOI: 10.1158/0008-5472.CAN-17-3760 
Meeting Viewpoint
www.aacrjournals.org Cancer Res; 78(9) May 1, 2018 | OF4 
MiRNA profiles can provide immunotherapy and radio-
therapy biomarkers of toxicity and response.
Treating limited tumor volume and its impact on clini-
cal outcome, including immunological consequences, were 
discussed in Session VII. There are preclinical data and 
clinical experience regarding the possibility to only treat 
a limited amount of the tumor or to use heterogeneous 
doses as a means of protecting normal tissue and elicit-
ing intratumoral and systemic immune attack. The actual 
delivered radiation dose accounting for tumor motion and 
dose scatter must be fully understood. Chandan Guha 
(Albert Einstein College of Medicine, Bronx, NY) empha-
sized that small field radiotherapy may be sufficient to 
stimulate robust antigen presentation, allowing the host to 
develop an immune response and at the same time protect 
the T-cell recruitment process. Silvia Formenti (Cornell 
University, New York, NY) presented data that dsDNA 
is sensed by cGAS, which is needed to activate the IFN1 
pathway via STING, but the complexity of the entire sensing-
response system is critical, with 3 × 8 Gy being more effec-
tive in developing an immune response when combined 
with checkpoint immunotherapy, compared with a higher 
single dose of 30 Gy. The mechanism was mediated by 
Trex1 induced by the highest doses of radiotherapy that 
then reduces IFNγ1 activation. Robert Griffin (University 
of Arkansas, Little Rock, AR) reviewed some of the early 
findings using “grid” therapy (heterogeneous dose distri-
bution) that was demonstrated in preclinical models. The 
observed alterations in gene expression and cell signal-
ing were presumed to be related to a bystander effect. He 
pointed out that cell killing in this approach is reduced 
by hypoxia and that antiangiogenic agents might enhance 
cell killing. Xiadong Wu (University of Miami, Miami, FL) 
also discussed how partial tumor irradiation could alter the 
stromal components of the tumor and thus affect immu-
notherapy or other tumor effects. However, many of the 
stromal changes induced by partial or whole volume tumor 
irradiation are not well defined, and it is unclear how to 
best utilize these changes. In contrast to the work of Griffin, 
Wu suggested that it might be important to enhance, rather 
than suppress, angiogenesis.
The closing discussions in Session VIII focused on how 
to build on the experience and success from radiotherapy 
and biology using the current and rapidly emerging tools 
of precision medicine. New paradigms in radiation biology 
promise to transform the use of radiation in cancer therapy. 
One of the new paradigms (in some ways an old paradigm) 
is hypofractionation, in which biological equivalent dose 
escalation can improve outcomes for certain cancers. With 
the ability to target lesions precisely, hypofractionation is 
paving a new path for combined modality therapy. It has 
become almost routine using stereotactic techniques for 
disease sites such as lung, pancreas, and prostate and offers 
an intriguing opportunity with immunotherapy. Deliver-
ing less total dose than extended conventional radiother-
apy using larger dose fractions, perhaps smaller volumes 
and short courses of treatment have sparked interest in 
immunotherapy.
There are many biological factors that might reasonably 
be expected to offer insights into how a course of radiation 
should be altered from traditional paradigms to improve 
local control rates. These include (a) pretreatment next-
generation sequencing to estimate the probability of local 
control after radiotherapy, (b) real-time assessment of DNA 
repair using measurement of CTC γH2AX, (c) hypoxia-
related resistance prediction during a course of therapy 
using serum HIF1α and CAIX, as well as imaging with 
oxygen-enhanced MRI or other contrast agents that can be 
used in PET, (d) real-time assessment of radiation response 
using periodic measurement of CTCs and ctDNA, and (e) 
pretherapy miRNA assessment, attempting to define pat-
terns of radiation sensitivity and prognosis. Essentially, 
the goal of such a program is to “surround” the course of 
therapy with the assessment of multiple biological param-
eters that, over time, would provide the clinician with key 
information regarding appropriate dose, dose per fraction, 
fractionation scheme, and radiation target volume, thus 
allowing them to personalize therapy and to adapt to the 
dynamically changing tumor biology before and during 
therapy in order to obtain better outcomes.
The “Shades of Gy” paradigm offers unique oppor-
tunities and also requires rigorous assessment of the 
dose delivered as the dose in Gy as a physical “ground 
truth” to which biological changes must be related. Clini-
cal radiotherapy is quite rigorous, taking into account 
organ motion, especially with hypofractionation. Further 
improvement is necessary as noted for the approaches 
employing heterogeneous doses and extremes of dose rate 
and size. The NCI Radiation Research Program has work-
shops planned in 2018 for targeted radionuclide therapy 
and GRID/Flash techniques. A new NCI UO1 grant pro-
gram to study combinations of drugs plus radiation is now 
being implemented. The paradigm of radiation-inducible 
molecular targets has recently been demonstrated and 
needs further study. The understanding of the biology of 
particle therapy has been limited by the availability of 
beam time, but the new data on immune modulation and 
toxicity serve as an incentive for preclinical research. The 
interest in adding radiation to immunotherapy (such as 
checkpoint inhibitors) needs to be coupled with preclini-
cal mechanism studies and biomarkers as being developed 
by immuno-oncologists. This “Shades of Gy” workshop is 
the initial presentation of this concept, with further dis-
semination forthcoming that proposes a “metastrategic 
plan” for radiation oncology and biology.
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